[1-27]

1. Ling, S.F. and J. Bluett, *Pharmacogenetics of methotrexate response in rheumatoid arthritis: an update.* Pharmacogenomics, 2020. **21**(1): p. 3-6.

2. Onishi, A., et al., *Genetic and clinical prediction models for the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study.* Pharmacogenomics J, 2019.

3. Muralidharan, N., et al., *Folyl polyglutamate synthethase (FPGS) gene polymorphisms may influence methotrexate adverse events in South Indian Tamil Rheumatoid Arthritis patients.* Pharmacogenomics J, 2019.

4. Luxembourger, C., et al., *A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients.* Pharmacogenomics J, 2019. **19**(4): p. 368-374.

5. Ling, S.F., et al., *Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients.* Pharmacogenomics J, 2019.

6. Jekic, B., N. Maksimovic, and T. Damnjanovic, *Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis.* Pharmacogenomics, 2019. **20**(17): p. 1235-1245.

7. He, X., et al., *Association between ABCB1 C3435T polymorphism and methotrexate treatment outcomes in rheumatoid arthritis patients: a meta-analysis.* Pharmacogenomics, 2019. **20**(5): p. 381-392.

8. Eektimmerman, F., et al., *Predictive genetic biomarkers for the efficacy of methotrexate in rheumatoid arthritis: a systematic review.* Pharmacogenomics J, 2019.

9. Eektimmerman, F., et al., *Validation of a clinical pharmacogenetic model to predict methotrexate nonresponse in rheumatoid arthritis patients.* Pharmacogenomics, 2019. **20**(2): p. 85-93.

10. Canet, L.M., et al., *Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients.* Pharmacogenomics J, 2019. **19**(1): p. 83-96.

11. Canet, L.M., et al., *Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients.* Pharmacogenomics J, 2019. **19**(6): p. 582.

12. Xiao, W., et al., *Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.* Pharmacogenomics, 2018. **19**(5): p. 383-392.

13. Taylor, J.C., et al., *Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients.* Pharmacogenomics J, 2018. **18**(4): p. 528-538.

14. Soukup, T., et al., *Are haplotypes in a single methotrexate pathway more predictive for response in rheumatoid arthritis than in different pathways?* Pharmacogenomics, 2018. **19**(5): p. 379-381.

15. Sode, J., et al., *Confirmation of an IRAK3 polymorphism as a genetic marker predicting response to anti-TNF treatment in rheumatoid arthritis.* Pharmacogenomics J, 2018. **18**(1): p. 81-86.

16. Massey, J., et al., *Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis.* Pharmacogenomics J, 2018. **18**(5): p. 657-664.

17. Maldonado-Montoro, M., et al., *Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis.* Pharmacogenomics J, 2018. **18**(1): p. 167-172.

18. Lopez-Rodriguez, R., et al., *Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.* Pharmacogenomics J, 2018. **18**(4): p. 539-545.

19. Eektimmerman, F., et al., *SLC04A1, SLC22A2 and SLC28A2 variants not related to methotrexate efficacy or toxicity in rheumatoid arthritis patients.* Pharmacogenomics, 2018. **19**(7): p. 613-619.

20. Sun, Y., et al., *Association of Fcgamma receptor type 2A and 3A genotypes with rheumatoid arthritis in Chinese population.* Pharmacogenomics, 2017. **18**(3): p. 255-264.

21. Song, Q.Q., et al., *Genetic variation in the glucocorticoid pathway involved in interindividual differences in the glucocorticoid treatment.* Pharmacogenomics, 2017. **18**(3): p. 293-316.

22. Nair, N., A.G. Wilson, and A. Barton, *DNA methylation as a marker of response in rheumatoid arthritis.* Pharmacogenomics, 2017. **18**(14): p. 1323-1332.

23. Mendrinou, E., et al., *FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFalpha inhibitors.* Pharmacogenomics J, 2017. **17**(3): p. 237-241.

24. Jenko, B., et al., *Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.* Pharmacogenomics J, 2017. **17**(5): p. 412-418.

25. Eektimmerman, F., et al., *Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis.* Pharmacogenomics, 2017. **18**(10): p. 945-953.

26. Chen, Y., et al., *Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis.* Pharmacogenomics, 2017. **18**(2): p. 175-195.

27. Bek, S., et al., *Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis.* Pharmacogenomics J, 2017. **17**(5): p. 403-411.